Literature DB >> 15569736

fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease.

Jane S Paulsen1, Janice L Zimbelman, Sean C Hinton, Douglas R Langbehn, Catherine L Leveroni, Michelle L Benjamin, Norman C Reynolds, Stephen M Rao.   

Abstract

BACKGROUND AND
PURPOSE: Functional MR imaging (fMRI) has been used to probe basal ganglia function in people with presymptomatic Huntington's disease (pre-HD). A previous fMRI study in healthy individuals demonstrated activation of the basal ganglia during a time-discrimination task. The current study was designed to examine the relative sensitivity of fMRI compared with that of behavioral testing and morphometric measurements in detecting early neurodegenerative changes related to Huntington's disease (HD).
METHODS: Pre-HD participants were assigned to two groups based on estimated years to diagnosis of manifest disease: close <12 years and far >or=12 years. Age at disease onset was estimated using a regression equation based on the number of trinucleotide CAG repeats. The time-discrimination task required participants to determine whether a specified interval was shorter or longer than a standard interval of 1200 milliseconds.
RESULTS: Participants in the close group performed more poorly on the time-task discrimination than did control subjects; however, no differences were observed between far participants and control subjects. Similarly, close participants had reduced bilateral caudate volume relative to that of control subjects, whereas far participants did not. On functional imaging, close participants had significantly less activation in subcortical regions (caudate, thalamus) than control subjects; far participants had an intermediate degree of activation. In contrast, far participants had hyperactivation in medial hemispheric structures (anterior cingulate, pre-supplementary motor area) relative to close and control subjects.
CONCLUSION: Hyperactivation of medial prefrontal regions compensated for reduced subcortical participation during time discrimination in pre-HD. This pattern of brain activation may represent an early neurobiologic marker of neuronal dysfunction.

Entities:  

Mesh:

Year:  2004        PMID: 15569736      PMCID: PMC8148746     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  41 in total

1.  AFNI: software for analysis and visualization of functional magnetic resonance neuroimages.

Authors:  R W Cox
Journal:  Comput Biomed Res       Date:  1996-06

2.  The accuracy and precision of timing of self-paced, repetitive movements in subjects with Parkinson's disease.

Authors:  D J O'Boyle; J S Freeman; F W Cody
Journal:  Brain       Date:  1996-02       Impact factor: 13.501

3.  Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse.

Authors:  J A Cherry; B E Thompson; V Pho
Journal:  Biochim Biophys Acta       Date:  2001-03-19

4.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Authors:  M Chen; V O Ona; M Li; R J Ferrante; K B Fink; S Zhu; J Bian; L Guo; L A Farrell; S M Hersch; W Hobbs; J P Vonsattel; J H Cha; R M Friedlander
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

5.  Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease.

Authors:  G J Harris; A M Codori; R F Lewis; E Schmidt; A Bedi; J Brandt
Journal:  Brain       Date:  1999-09       Impact factor: 13.501

6.  Cognitive scores in carriers of Huntington's disease gene compared to noncarriers.

Authors:  T Foroud; E Siemers; D Kleindorfer; D J Bill; M E Hodes; J A Norton; P M Conneally; J C Christian
Journal:  Ann Neurol       Date:  1995-05       Impact factor: 10.422

7.  Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons.

Authors:  E H Aylward; J Brandt; A M Codori; R S Mangus; P E Barta; G J Harris
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

8.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

9.  Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study.

Authors:  S E Starkstein; J Brandt; F Bylsma; C Peyser; M Folstein; S E Folstein
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

10.  The differential effects of haloperidol and methamphetamine on time estimation in the rat.

Authors:  A V Maricq; R M Church
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more
  85 in total

1.  Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex.

Authors:  Adam G Walker; Jason R Ummel; George V Rebec
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

2.  Stability of resting fMRI interregional correlations analyzed in subject-native space: a one-year longitudinal study in healthy adults and premanifest Huntington's disease.

Authors:  Tyler M Seibert; D S Adnan Majid; Adam R Aron; Jody Corey-Bloom; James B Brewer
Journal:  Neuroimage       Date:  2011-09-10       Impact factor: 6.556

3.  "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness.

Authors:  Kevin Duff; Jane S Paulsen; Leigh J Beglinger; Douglas R Langbehn; Chiachi Wang; Julie C Stout; Christopher A Ross; Elizabeth Aylward; Noelle E Carlozzi; Sarah Queller
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2010       Impact factor: 2.198

4.  Challenges assessing clinical endpoints in early Huntington disease.

Authors:  Jane S Paulsen; Chiachi Wang; Kevin Duff; Roger Barker; Martha Nance; Leigh Beglinger; David Moser; Janet K Williams; Sheila Simpson; Douglas Langbehn; Daniel P van Kammen
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

5.  Variability in interval production is due to timing-dependent deficits in Huntington's disease.

Authors:  Ashwini K Rao; Karen S Marder; Jasim Uddin; Brian C Rakitin
Journal:  Mov Disord       Date:  2014-08-22       Impact factor: 10.338

6.  Long-term test-retest reliability of functional MRI in a classification learning task.

Authors:  Adam R Aron; Mark A Gluck; Russell A Poldrack
Journal:  Neuroimage       Date:  2005-09-01       Impact factor: 6.556

Review 7.  Neural networks engaged in milliseconds and seconds time processing: evidence from transcranial magnetic stimulation and patients with cortical or subcortical dysfunction.

Authors:  Giacomo Koch; Massimiliano Oliveri; Carlo Caltagirone
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-07-12       Impact factor: 6.237

Review 8.  "Pre-symptomatic" Huntington's disease.

Authors:  Kevin Duff; Leigh J Beglinger; Jane S Paulsen
Journal:  Handb Clin Neurol       Date:  2008

Review 9.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

10.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.